[EN] COMBINATION OF ANTIBODY-DRUG CONJUGATE AND PARP1 SELECTIVE INHIBITOR<br/>[FR] ASSOCIATION D'UN ANTICORPS CONJUGUÉ ET D'UN INHIBITEUR SÉLECTIF DE LA PARP1
申请人:ASTRAZENECA UK LTD
公开号:WO2022074617A1
公开(公告)日:2022-04-14
A pharmaceutical product for administration of an anti-HER2 antibody-drug conjugate in combination with a PARP1 selective inhibitor is provided. The anti-HER2 antibody drug conjugate is an antibody-drug conjugate in which a drug-linker represented by the following formula (wherein A represents the connecting position to an antibody) is conjugated to an anti-HER2 antibody via a thioether bond. Also provided is a therapeutic use and method wherein the antibody-drug conjugate and the PARP1 selective inhibitor are administered in combination to a subject: Formula (I).